Skip to main content

RT @doctorRBC: Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabo

Social Author Name
Robert B Chao, MD
Tweet Content
Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819 https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
Show on Archive Page
On
Display in Search Results
On
PDQ
Off